Compare Global E Online Ltd (GLBE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Heron Therapeutics Inc — how do they compare? Global E Online Ltd trades at $40.03 (market cap $6.54B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Global E Online Ltd is far larger — about 88.3× Heron Therapeutics Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Heron Therapeutics Inc for 35 Days on average.
| GLBE | HRTX | |
|---|---|---|
Market Cap | $6.54B | $74.04M |
Volume | 1,011,873 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $1.49 |
52-Week Low | $27.54 | $0.27 |
Typical Hold Time | 21 Days | 35 Days |
Enterprise Value | $6.04B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year outlook, with revenue growth of 39% year-over-year. Recent news includes the appointment of Tomer Gold as Chief Revenue Officer and significant insider selling by executives.
The outlook is positive with robust analyst support—93% buy ratings and a $48.86 consensus price target implying 25% upside. Key risks include insider selling pressure and execution challenges in maintaining high growth. Earnings growth and margin expansion remain primary catalysts for stock appreciation.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
